Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Queensland Health
AstraZeneca
QuintilesIMS
Healthtrust
McKesson
Accenture
US Department of Justice
Johnson and Johnson

Generated: April 22, 2018

DrugPatentWatch Database Preview

MAXALT-MLT Drug Profile

« Back to Dashboard

When do Maxalt-mlt patents expire, and when can generic versions of Maxalt-mlt launch?

Maxalt-mlt is a drug marketed by Merck and is included in one NDA.

The generic ingredient in MAXALT-MLT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
Summary for MAXALT-MLT
US Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Clinical Trials: 6
Drug Prices:see details
DailyMed Link:MAXALT-MLT at DailyMed
Drug patent expirations by year for MAXALT-MLT

US Patents and Regulatory Information for MAXALT-MLT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-002 Jun 29, 1998 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for MAXALT-MLT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MAXALT-MLT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2006-02-17

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Federal Trade Commission
Merck
Teva
Julphar
Cipla
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.